Skip to main content
. Author manuscript; available in PMC: 2018 Dec 3.
Published in final edited form as: Abdom Radiol (NY). 2018 Nov;43(11):3166–3175. doi: 10.1007/s00261-018-1581-5

Fig. 5.

Fig. 5.

Treatment effect monitoring by contrast-enhanced ultrasound after trans-arterial chemoembolization (TACE) of hepatocellular carcinoma. (A) Post-contrast T1-weighted fat suppressed MRI demonstrating a 2.8 × 2.6 × 2.5 cm segment VI LI-RADS 5 lesion (arrow) with arterial phase enhancement (and washout on delayed imaging) before TACE treatment. (B) Gray-scale ultrasound with difficulty delineating the lesion bed post-treatment. (C) Contrast-enhanced ultrasound of the same ultrasound window demonstrating the lesion with partial treatment response and some residual enhancement (arrow) concerning for viable tumor.